Last updated on February 2018

Nintedanib (BIBF 1120) in Mesothelioma


Brief description of study

This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.

Clinical Study Identifier: NCT01907100

Contact Investigators or Research Sites near you

Start Over

Boehringer Ingelheim Call Center

Merc Oncology
Pretoria, South Africa
2.63miles

Boehringer Ingelheim Call Center

Wilgers Oncology Centre
Pretoria, South Africa
7.54miles